Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022
March 03 2022 - 4:16PM
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company
advancing new treatments for patients suffering from serious
diseases underserved by current therapies, today announced it will
report its financial results from the fourth quarter and full year
ended December 31, 2021, after the financial markets close
on Thursday, March 10, 2022.
The Company’s management team will host a conference call
at 4:30 p.m. ET on Thursday, March 10, 2022. To
access the call, please dial 1-877-407-0789 in
the U.S., or 1-201-689-8562 outside
the U.S., and provide the conference ID number: 13727096.
To access the live webcast, please visit the “Events” page in the
Investors section of the Viridian Therapeutics, Inc. website.
Following the live webcast, an archived version of the call will
also be available on the website.
Thursday, March 10 at 4:30 p.m.
ET
Domestic: |
1-877-407-0789 |
International: |
1-201-689-8562 |
Conference ID: |
13727096 |
Webcast: |
Webcast Link |
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing
new treatments for patients suffering from serious diseases but
underserved by today’s therapies. Viridian’s most advanced program,
VRDN-001, is a differentiated monoclonal antibody targeting
insulin-like growth factor-1 receptor (IGF-1R), a clinically and
commercially validated target for the treatment of thyroid eye
disease (TED). Viridian’s second product candidate, VRDN-002, is a
distinct anti-IGF-1R antibody that incorporates half-life extension
technology and is designed to support administration as a
convenient, low-volume, subcutaneous injection. TED is a
debilitating autoimmune disease that causes inflammation and
fibrosis within the orbit of the eye which can cause double vision,
pain, and potential blindness. Patients with severe disease often
require multiple remedial surgeries to the orbit, eye muscles and
eyelids. Viridian is based in Waltham, Massachusetts.
Investor and Media Contact:John JordanViridian
TherapeuticsVice President, Investor Relations& Corporate
Communications617-272-4691IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Jul 2023 to Jul 2024